Advertisement
Australia markets closed
  • ALL ORDS

    7,996.50
    -10.60 (-0.13%)
     
  • AUD/USD

    0.6527
    +0.0001 (+0.02%)
     
  • ASX 200

    7,735.80
    -9.80 (-0.13%)
     
  • OIL

    80.09
    +0.12 (+0.15%)
     
  • GOLD

    2,096.30
    +0.60 (+0.03%)
     
  • Bitcoin AUD

    98,261.48
    +3,687.51 (+3.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

ALTERITY THERAPEUTICS LIMITED
ALTERITY THERAPEUTICS LIMITED

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required.

The call will be hosted by Alterity’s CEO Dr. David Stamler who will discuss the ATH434 efficacy data in primates released today along with recent clinical progress.

Webcast details

 

 

 

AUSTRALIA PARTICIPANTS:

 

Date:

Wednesday, 6 December 2023

 

Time:

9:00 a.m. AEDT (Sydney/Melbourne)

 

 

 

UNITED STATES PARTICIPANTS:

 

Date:

Tuesday, 5 December 2023

 

Time:

2:00 p.m. Pacific Time

 

 

5:00 p.m. Eastern Time


Register for the Zoom webcast:

https://us02web.zoom.us/webinar/register/WN_9Lv1OWMtSSSqdJrRsKRiTA#/registration
Registration is required and dial in details will be sent directly upon registration.

Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation. Investors are also able to submit questions in advance to Hannah Howlett at we-aualteritytherapeutics@we-worldwide.com

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064

U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386